Researchers are actively investigating how to overcome resistance to CDK4/6 inhibitors. A Phase 1b trial (TAKTIC) evaluated ipatasertib, an AKT pathway inhibitor, combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → and palbociclib in patients with treatment-refractory HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative metastatic disease. A Phase 3 trial (NCT04305496) compared capivasertib plus fulvestrant against placebo plus fulvestrant in locally advanced or metastatic HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative breast cancer. In HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive disease, a Phase 3 study (NCT05894239) is examining inavolisib combined with a pertuzumab-trastuzumab fixed-dose combination in PIK3CA-mutated HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive metastatic breast cancer. For TNBC, a Phase 3 trial (NCT06103864) is testing datopotamab deruxtecan (Dato-DXd) with or without durvalumab against chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → plus pembrolizumab in PD-L1-positive metastatic or locally recurrent disease. Another Phase 3 study (ASCENT-05, NCT05633654) is evaluating sacituzumab govitecan plus pembrolizumab versus capecitabine for TNBC with residual invasive disease after surgery and neoadjuvant therapy. In early HR+ disease, a Phase 3b trial (NCT05827081) is examining ribociclib combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation →. A pooled analysis from five randomized trials found that omitting axillary lymph node surgery reduces surgical morbidity without compromising survival, though it also limits staging data that determines CDK4/6 inhibitor eligibility. A Phase 3 trial (NCT06058377) is adding durvalumab to standard chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → for Stage II-III breast cancer. Novel radiopharmaceutical approaches, including lutetium-177-labeled NeoB targeting the gastrin-releasing peptide receptor combined with ribociclib and fulvestrant (NCT05870579), are in Phase 1 testing.
Where the evidence stands
CDK4/6 inhibitors combined with endocrine therapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → have the strongest evidence base in HR+/HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-negative advanced breast cancer, supported by multiple Phase 3 trials and meta-analysesA statistical method that combines results from multiple studies for a stronger conclusion.Click for full explanation → confirming improvements in progression-free and overall survivalThe percentage of patients still alive after a set period — a key clinical trial endpoint.Click for full explanation →. HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-directed therapies, particularly trastuzumab deruxtecan, have Phase 3 data in both HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive and HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-low settings. ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → with pembrolizumab for TNBC is supported by Phase 3 evidence. AKT pathway inhibitors such as capivasertib are approved in select patients, while newer agents like inavolisib are in ongoing Phase 3 evaluation. Novel antibody-drug conjugates such as datopotamab deruxtecan are now in Phase 3 testing. De-escalation of axillary surgery is supported by pooled trial data, but its interaction with treatment eligibility decisions is still being worked out. Radiopharmaceutical strategies remain early-stage.
What this means for people affected
Breast cancer treatment options have expanded substantially across all major subtypes, and treatment selection depends heavily on tumor biology, molecular markers, and prior therapy history. Hormone receptor-positive disease has multiple targeted options that extend remission in advanced settings. HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive disease has highly effective antibody-drug conjugates available. TNBC, historically the hardest subtype to treat, now has immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → and newer targeted agents. The active research pipeline addresses resistance to established treatments, explores ways to reduce surgical burden, and tests new drug combinations, suggesting the landscape will continue to evolve.
Last updated May 4, 2026
Recent research findings
Understanding evidence levels▼
PreclinicalLab or cell studies — no human data yet.
Animal StudyResults in animals only — may not apply to humans.
Phase 1 TrialFirst-in-human safety testing in small groups.
Phase 2 TrialEarly effectiveness testing in a larger group.
Phase 3 TrialLarge controlled trial — the strongest trial evidence.
Observational StudyPatterns observed in populations — not a controlled trial.
ReviewSummary analysis of multiple existing studies.
Meta-AnalysisStatistical pooling of results from multiple studies.
ReviewSummary and analysis of existing published studies.Published: May 18, 2026
Mapping Research on Preventing a Common Side Effect of Breast Cancer ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation →
Researchers analyzed a large collection of studies on a type of medication called long-acting G-CSF, which helps prevent a serious side effect of breast cancer chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → called febrile neutropenia. They found that the research on this topic has grown rapidly and is now focusing on how to implement it in real-world practice. The study aimed to provide a clear overview of the current state of research on this topic.
Why it matters: This study may help identify future research priorities and provide a framework for navigating the complex evidence base on febrile neutropenia prevention.
The study analyzed a large collection of studies, but it did not present any new data or results.
ReviewSummary and analysis of existing published studies.Published: May 18, 2026
Genomic Science and Breast Cancer in Males
Researchers looked at how genomic science can help identify and treat breast cancer in males. They found that individuals with a family history of breast cancer may be at higher risk. This is an area where nurses can play a key role in providing care.
Why it matters: This research highlights the importance of genomic science in understanding and treating breast cancer in males, particularly in those with a family history.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 18, 2026
Obesity Linked to Poorer Outcomes in Young Women with Certain Breast Cancer
Researchers studied 5,094 premenopausal women with a specific type of breast cancer in China. They found that women who were obese had poorer outcomes compared to those who were underweight, normal weight, or overweight. The study suggests that obesity may be an independent risk factor for breast cancer recurrence in these women.
Why it matters: This finding may help doctors better understand how to treat young women with this type of breast cancer and how to manage their weight to improve their prognosis.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 18, 2026
Kenyan Study Tests New Approach to Increase Breast and Cervical Cancer Screenings
Researchers in Kenya are testing a new program called C3Link to see if it can increase the number of women getting breast and cervical cancer screenings. The program includes community and clinic strategies to address barriers to screening. The study will compare the C3Link program to usual care.
Why it matters: This study could provide insights into how to improve cancer screening rates in low-resource settings.
✦ Significant findingA meaningful signal from later-stage research, or a strong phase 2 result that stands out from routine findings.Meta-AnalysisStatistical pooling of results from multiple studies.Published: May 16, 2026
Yoga May Help Reduce Depression in Breast Cancer Patients
Researchers analyzed 21 studies on yoga and depression in breast cancer patients. They found that yoga may help reduce depression levels, but the effect varied depending on the treatment the patient was receiving. The study suggests that yoga could be a useful addition to other treatments for depression in breast cancer patients.
Why it matters: This finding could help doctors and patients consider yoga as a complementary treatment for depression during breast cancer therapy.
Efficacy
Yoga significantly reduced depression levels [SMD = -0.58, 95% CI (-0.83, -0.32), P < 0.00001].
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 16, 2026
Pembrolizumab May Help Treat Rare Breast Cancer
Researchers treated a woman with a rare and aggressive form of breast cancer called metaplastic breast carcinoma using a combination of chemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → and pembrolizumab, an immunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → drug. The treatment led to a significant reduction in the size of her metastases, but it also caused some side effects. The patient's cancer did not progress for 30 months after starting treatment.
Why it matters: This finding may lead to new treatment options for patients with metastatic metaplastic breast carcinoma.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 16, 2026
Cognitive-Behavioral Therapy Helps Women with Advanced Breast Cancer
Researchers tested a four-session group therapy program for women with HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive metastatic breast cancer. They found that participants experienced improvements in psychological distress, depression, and stigma after the intervention. However, the study had a small sample size and more research is needed.
Why it matters: This finding could lead to the development of more effective psychological support for women with advanced breast cancer.
A small sample size of 13 participants was involved in this study.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 16, 2026
Combining Two Treatments May Help Fight Aggressive Breast Cancer
Researchers studied how a molecule called CD24 affects breast cancer cells that have a protein called HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →. They found that knocking down CD24 made the cancer cells less aggressive and more likely to die. In lab experiments, combining this approach with a common cancer treatment called trastuzumab was effective against HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive breast cancer.
Why it matters: This finding could lead to new treatment options for people with HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-positive breast cancer.
This study was conducted in lab experiments and has not been tested in people yet.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 16, 2026
Body Compassion May Help Women with Breast Cancer
Researchers studied 214 women with breast cancer to see how body compassion affects their mental health. They found that women with low body compassion were more likely to feel demoralized, fear cancer recurrence, and have body image concerns. Body compassion may help reduce these negative feelings.
Why it matters: This finding highlights the importance of body compassion-based psychological interventions for improving mental health and quality of life in women with breast cancer.
Lab StudyLaboratory experiments on cells or tissue. No human or animal data.Published: May 16, 2026
Betulinic acid may help fight breast cancer
Researchers studied how betulinic acid affects breast cancer cells in lab experiments. They found that it may help kill cancer cells and reduce the activity of a gene called miR-21. However, more research is needed to confirm these findings.
Why it matters: This study could help scientists better understand how to treat breast cancer and identify new potential treatments.
This study was conducted in lab experiments and involved a specific type of breast cancer cell line.
ReviewSummary and analysis of existing published studies.Published: May 15, 2026
Understanding Inflammatory Breast Cancer
Researchers gathered to discuss advances in inflammatory breast cancer (IBC), a rare and aggressive form of breast cancer. They focused on the disease's biology, treatment options, and new technologies to improve diagnosis and care. The goal is to improve outcomes for patients with IBC.
Why it matters: This research aims to improve our understanding of IBC and develop more effective treatments for patients with this aggressive form of breast cancer.
Observational StudyPatterns observed in populations over time, not a controlled experiment.Published: May 15, 2026
Breast Cancer Trends in China Compared to 20 Countries
Researchers analyzed breast cancer patterns in China and compared them to 20 other countries. They found that breast cancer incidence in China increased by over 360% between 1990 and 2021, with a significant increase in the age-standardized incidence rate. The study also projected future trends in breast cancer incidence and mortality in China.
Why it matters: This study highlights the urgent need for enhanced prevention and targeted screening strategies in China to mitigate the growing disease burden.
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →- Advanced Breast Cancer
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → at 18 Months in Patients Treated for Breast Cancer
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With MutationsA change in DNA sequence that can drive cancer development.Click for full explanation → of the Human Epidermal Growth Factor Receptor 2 (HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →)
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →-) Breast Cancer
Targeted TherapyDrugs that block specific molecules that cancer cells need to grow.Click for full explanation → Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Genetic & Pathological Studies of BRCA1Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →/BRCA2Genes whose mutations significantly raise the risk of breast and ovarian cancers.Click for full explanation →: Associated Tumors & Blood Samples
